Margaret Stanley1. 1. Department of Pathology, University of Cambridge, Cambridge, UK. mas1001@cam.ac.uk
Abstract
PURPOSE OF REVIEW: Prophylactic human papillomavirus (HPV) L1 virus like particle (VLP) vaccines have been shown, in large randomized controlled clinical trials, to be very immunogenic, well tolerated and highly efficacious against ano-genital disease caused by the vaccine HPV types. However, these vaccines, at the present, protect against only two of the 15 oncogenic genital HPV types, they are expensive, delivered by intramuscular injection and require a cold chain. RECENT FINDINGS: The challenges are to develop cheap, thermostable vaccines that can be delivered by noninjectable methods that provide long-term (decades) protection at mucosal surfaces to most, if not all, oncogenic HPV types that is as good as the current VLP vaccines. Polyvalent VLP vaccines covering several oncogenic types are in clinical trials. The most promising of the non-VLP second generation vaccines include L1 capsomers and L2 protein and peptides, suitably adjuvanted. Recent data on the mechanism of viral entry and the dynamics of the interaction of the viral capsid proteins L1 and L2 with the cell surface provide a rationale for the protection offered by these new approaches. SUMMARY: These second generation vaccines are immunogenic and can provide broad protection but are either at early stage in clinical trial or not in trials. The current VLP prophylactic vaccines are likely to be the only option for the coming decade.
PURPOSE OF REVIEW: Prophylactic human papillomavirus (HPV) L1 virus like particle (VLP) vaccines have been shown, in large randomized controlled clinical trials, to be very immunogenic, well tolerated and highly efficacious against ano-genital disease caused by the vaccine HPV types. However, these vaccines, at the present, protect against only two of the 15 oncogenic genital HPV types, they are expensive, delivered by intramuscular injection and require a cold chain. RECENT FINDINGS: The challenges are to develop cheap, thermostable vaccines that can be delivered by noninjectable methods that provide long-term (decades) protection at mucosal surfaces to most, if not all, oncogenic HPV types that is as good as the current VLP vaccines. Polyvalent VLP vaccines covering several oncogenic types are in clinical trials. The most promising of the non-VLP second generation vaccines include L1 capsomers and L2 protein and peptides, suitably adjuvanted. Recent data on the mechanism of viral entry and the dynamics of the interaction of the viral capsid proteins L1 and L2 with the cell surface provide a rationale for the protection offered by these new approaches. SUMMARY: These second generation vaccines are immunogenic and can provide broad protection but are either at early stage in clinical trial or not in trials. The current VLP prophylactic vaccines are likely to be the only option for the coming decade.
Authors: Mahboobeh Safaeian; Carolina Porras; Yuanji Pan; Aimee Kreimer; John T Schiller; Paula Gonzalez; Douglas R Lowy; Sholom Wacholder; Mark Schiffman; Ana C Rodriguez; Rolando Herrero; Troy Kemp; Gloriana Shelton; Wim Quint; Leen-Jan van Doorn; Allan Hildesheim; Ligia A Pinto Journal: Cancer Prev Res (Phila) Date: 2013-11
Authors: Carlo Zanotto; Eleana Pozzi; Sole Pacchioni; Massimiliano Bissa; Carlo De Giuli Morghen; Antonia Radaelli Journal: J Transl Med Date: 2011-11-04 Impact factor: 5.531
Authors: Arati Mane; Amit Nirmalkar; Arun R Risbud; Sten H Vermund; Sanjay M Mehendale; Vikrant V Sahasrabuddhe Journal: PLoS One Date: 2012-06-19 Impact factor: 3.240
Authors: Paul K S Chan; María Alejandra Picconi; Tak Hong Cheung; Lucia Giovannelli; Jong Sup Park Journal: Crit Rev Clin Lab Sci Date: 2012 Jul-Aug Impact factor: 6.250